Final installment of the Over $10 series. If Part 1 was the top shelf and Part 2 was the engine room, this is the farm system plus a few surprises. Some of these names changed significantly during verification. TBPH had a Phase 3 failure and is now in strategic review. PLSE pivoted to cardiac ablation with 96% success data. DBVT has two BLA filings on track for 2026. The scores below reflect what’s actually happening right now, not what I assumed two weeks ago.